GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
G

Gencurix 229000.KQ · KRW

Health Care · KOSDAQ · 🇰🇷 South Korea

Compare

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Gencurix

Its shares trade on KOSDAQ under the ticker 229000.KQ. It has been listed since 27 October 2015. In the fiscal year to 31 December 2025, it reported revenue of ₩7.55bn and a net loss of ₩7.39bn. At that date it held total assets of ₩32.11bn and shareholders' equity of ₩16.37bn.

Gencurix, Inc. is engaged in developing and manufacturing of cancer diagnostic test kits. The company is headquartered in Seoul, Seoul. The company went IPO on 2015-10-27. In addition, the Company is involved in the manufacturing and sale of breast cancer test (BCT) kits, Korean genetic polymorphism diagnostic kits, lung cancer and colorectal cancer diagnostic kits. The BCT kits are used for analyzing the expression level of the cancer-related gene. The products are sold under the name of GenesWell.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Health Care Equipment & Supplies
Listed since
27 Oct 2015

Leadership

Pay as last reported

  • Mr. Sang Rae ChoChief Executive Officer, Director
  • Mr. Jeong Do ParkVice President
  • Mr. Yeong Ho MoonVice President
  • Mr. Jeong Hui ChoInternal Auditor, Non-Executive Director
  • Ms. Mi Ran KangAssistant Managing Director
  • Jin Gu JungDirector
  • Mr. Hyeon Wuk ParkDirector
  • Mr. Se Hyeon AhnNon-Executive Independent Director
  • Mr. Jun Seok ChoiNon-Executive Independent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Gencurix Inc develops cancer diagnostic test kits in South Korea.
  • The company manufactures breast cancer test kits for gene analysis.
  • Products are sold under the brand name GenesWell globally.

Weaknesses

  • The company is headquartered in Seoul, South Korea.
  • Gencurix Inc went public on 27 October 2015.
  • The firm operates within the Health Care sector.

Opportunities

  • Gencurix Inc sells Korean genetic polymorphism diagnostic kits locally.
  • The firm produces lung cancer diagnostic kits for patients.
  • Colorectal cancer diagnostic kits expand the product portfolio significantly.

Threats

  • The company relies on the Health Care industry standards.
  • Gencurix Inc faces competition in the South Korean market.
  • Breast cancer test kits require strict regulatory compliance.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.